De Novo Biosynthesis of Antidepressant Psilocybin in Escherichia coli
Microbial Biotechnology April 1, 2025 Zhangrao Huang, Yongpeng Yao, Rong Di et al. 12 citations
ABSTRACT Psilocybin, a tryptamine‐derived alkaloid, has been granted Breakthrough Therapy designation by the U.S. FDA for treatment‐resistant depression, underscoring its clinical importance. Therefore, sustainable and economic production is urgently needed. Manufacturing of psilocybin in Escherichia coli has drawn great attention. However, due to the low expression and activity of the...